Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin short-term effects on peak VO2 in HFrEF with type 2 diabetes
2018-002614-12Phase 4Completed
- Sponsor
- INCLIVA Biomedical Research Institute
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in heart failure with reduced ejection fraction (HFrEF) and type 2 diabetes mellitus (T2DM) comparing Dapagliflozin with Placebo (2 arms). Primary endpoint: Change in peak VO2. Started Jan 2019; status: completed.
02
Drugs
dapagliflozin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2018-002614-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002614-12.